Eric Lefkofsky is a businessman and a technological expert. He among his partners are the brain behind the Tempus Inc. He is also the chief executive officer of this company. In this establishment, he has been pooling resources together in an attempt to realize a more effective treatment to those with cancer. Eric has been an investor in various sectors of the economy. He has been one of the founding partners at the Light bank; a company that focuses on disruptive technological projects.
Eric Lefkofsky is a graduate of Lathrup High school. He then proceeded to the Michigan University where he undertook a degree in law. In the year 1991, he graduated with honors. He went ahead to enroll for post graduate studies in the same University. He was conferred with a Juris doctorate in the year 1993.
As the president of the Tempus Company, Eric Lefkofsky primary role is the implementation of ideas and resolutions passed during board meetings. As a CEO, he oversees a research project that it is aimed at discovering the best treatment plans for the cancerous patients.
Unlike other research organizations, Tempus Inc. takes a different approach to the subject matter. Instead of striving to get a single ultimate cure, the research focuses on giving a variety of options that together lead to the same goal. In this way, the group equips various medical doctors with a range of choices on how to best treat a cancerous patient. To achieve this target, the firm makes use of personalized treatment plans and available data from various practicing doctors across the globe. Tempus Inc. then uses the molecular therapy concept to analyze the data and make any recommendation.
For the firm to make a concrete and valuable recommendation, Tempus Inc. collects larger samples of genomic data for analysis. The analysis takes into consideration various options that the doctor can apply. An algorithm is introduced to come up with the best possible option given the circumstance. The result is real-time analysis of data leading to better care services for the patients. The program is even made easier courtesy of the various patients who have been working with the program. The firm hopes that patients with all forms of cancer will be able to appreciate its initiative.